A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

NCT05678257 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

180

Enrollment

OTHER

Sponsor class

Stopped A pre-planned initial analysis concluded that the study was unlikely to achieve its primary objective of demonstrating superior progression-free survival. Based on the Steering Committee's recommendation, the Sponsor has closed the study.

Conditions

Colorectal Cancer
Colorectal Neoplasms
Colorectal Adenocarcinoma
Colorectal Cancer Metastatic
Neoplasm, Colorectal

Interventions

DRUG: Fosifloxuridine Nafalbenamide
DRUG: Leucovorin
DRUG: Irinotecan
BIOLOGICAL: Bevacizumab
DRUG: 5-FU

Sponsor

NuCana plc